Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
This empowers countries with superior negotiating powers a leverage, [ii] typically developed nations in the context of developed-developing country partnerships. The implementation of TRIPS-Plus provisions can also readily facilitate the emergence of monopoly power for brand-name pharmaceutical companies. [v]
Let's personalize your content